- Home
- MGIC vs VCEL Comparison
MGIC vs VCEL Comparison
Compare MGIC & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGIC | VCEL |
|---|---|---|
| Founded | 1983 | 1989 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.3M | 2.0B |
| IPO Year | 1991 | 1997 |
Fundamental Metrics
Financial Performance| Metric | MGIC | VCEL |
|---|---|---|
| Price | $26.38 | $36.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $18.00 | ★ $57.50 |
| AVG Volume (30 Days) | 42.3K | ★ 607.3K |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | 16.15 | ★ 236.54 |
| EPS | ★ 0.81 | 0.25 |
| Revenue | ★ $603,216,000.00 | $258,716,999.00 |
| Revenue This Year | $12.87 | $17.86 |
| Revenue Next Year | $6.23 | $18.55 |
| P/E Ratio | ★ $32.45 | $148.94 |
| Revenue Growth | 12.65 | ★ 14.05 |
| 52 Week Low | $11.36 | $29.24 |
| 52 Week High | $27.44 | $63.00 |
Technical Indicators
Market Signals| Indicator | MGIC | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 44.67 |
| Support Level | $26.25 | $35.53 |
| Resistance Level | $26.95 | $38.15 |
| Average True Range (ATR) | 0.72 | 1.21 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 50.00 | 48.36 |
Price Performance
Historical ComparisonAbout MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.